Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.
Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.
复制标题
DOI：
10.1038/s41586-021-03908-2
复制
发表时间：
2021-09
期刊：
影响因子：
64.8
通讯作者：
Uhlemann AC
中科院分区：
文献类型：
--
作者：
Annavajhala MK;Mohri H;Wang P;Nair M;Zucker JE;Sheng Z;Gomez-Simmonds A;Kelley AL;Tagliavia M;Huang Y;Bedford T;Ho DD;Uhlemann AC
近几个月来，SARS-CoV-2感染在地球仪各地激增，同时伴随着相当大的病毒进化。刺突蛋白的广泛突变可能威胁疫苗和治疗性单克隆抗体的功效。两个值得关注的标志性刺突突变是E484 K，它在抗体中和活性的丧失中起着至关重要的作用，以及N501 Y，它是B.1.1.7谱系在全球范围内快速传播的驱动因素。在这里，我们报告了包含E484 K的变异谱系B.1.526（也称为Iota变异）的出现，以及它在2021年初在纽约市的主导地位。该变体对临床使用的两种治疗性单克隆抗体具有部分或完全抗性，并且不易被从SARS-CoV-2感染中恢复的个体的血浆或接种个体的血清中和，从而构成适度的抗原挑战。B.1.526谱系的存在现已在美国所有50个州和许多其他国家报道。B.1.526在纽约迅速取代了早期的血统，估计传播优势为35%。这些传播动力学，连同其E484 K亚系的相对抗体抗性，可能促成了B.1.526的急剧上升和快速传播。尽管SARS-CoV-2 B.1.526最初在该地区的增长速度超过了B.1.1.7，但其增长随后随着B.1.1.7及其变种的增长而放缓。SARS-CoV-2变异株B.1.526的传播动力学表明，对抗体中和的抗性可能在其他变异株中进化，并有助于COVID-19的传播。
SARS-CoV-2 infections have surged across the globe in recent months, concomitant with considerable viral evolution. Extensive mutations in the spike protein may threaten the efficacy of vaccines and therapeutic monoclonal antibodies. Two signature spike mutations of concern are E484K, which has a crucial role in the loss of neutralizing activity of antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here we report the emergence of the variant lineage B.1.526 (also known as the Iota variant), which contains E484K, and its rise to dominance in New York City in early 2021. This variant is partially or completely resistant to two therapeutic monoclonal antibodies that are in clinical use and is less susceptible to neutralization by plasma from individuals who had recovered from SARS-CoV-2 infection or serum from vaccinated individuals, posing a modest antigenic challenge. The presence of the B.1.526 lineage has now been reported in all 50 states in the United States and in many other countries. B.1.526 rapidly replaced earlier lineages in New York, with an estimated transmission advantage of 35%. These transmission dynamics, together with the relative antibody resistance of its E484K sub-lineage, are likely to have contributed to the sharp rise and rapid spread of B.1.526. Although SARS-CoV-2 B.1.526 initially outpaced B.1.1.7 in the region, its growth subsequently slowed concurrently with the rise of B.1.1.7 and ensuing variants. The dynamics of the spread of the SARS-CoV-2 variant B.1.526 suggest that resistance to neutralization by antibodies may evolve in other variants and contribute to the spread of COVID-19.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
16.6
作者：
Smyrlaki I;Ekman M;Lentini A;Rufino de Sousa N;Papanicolaou N;Vondracek M;Aarum J;Safari H;Muradrasoli S;Rothfuchs AG;Albert J;Högberg B;Reinius B
通讯作者：
Reinius B
DOI：
10.1016/s0140-6736(21)00183-5
发表时间：
2021-02-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Sabino EC;Buss LF;Carvalho MPS;Prete CA Jr;Crispim MAE;Fraiji NA;Pereira RHM;Parag KV;da Silva Peixoto P;Kraemer MUG;Oikawa MK;Salomon T;Cucunuba ZM;Castro MC;de Souza Santos AA;Nascimento VH;Pereira HS;Ferguson NM;Pybus OG;Kucharski A;Busch MP;Dye C;Faria NR
通讯作者：
Faria NR
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
5.3
作者：
Sagulenko P;Puller V;Neher RA
通讯作者：
Neher RA